Tumor-educated platelets: A new field in breast cancer diagnosis

IF 3.2 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-07-03 DOI:10.1016/j.cca.2025.120467

Xiaoting Yang, Xiaojuan Li, Xilong Wang, Yuting Yang, Honggang Wang, Yang Duan

{"title":"Tumor-educated platelets: A new field in breast cancer diagnosis","authors":"Xiaoting Yang, Xiaojuan Li, Xilong Wang, Yuting Yang, Honggang Wang, Yang Duan","doi":"10.1016/j.cca.2025.120467","DOIUrl":null,"url":null,"abstract":"<div><div>Tumor-educated platelets (TEPs) represent a novel approach in liquid biopsy, offering new perspectives for diagnosing, treating, and monitoring breast cancer. Unlike traditional histopathological biopsies—the current diagnostic gold standard—TEP-based detection is minimally invasive, requiring only peripheral blood samples and overcoming limitations of repeated invasive procedures. TEPs reflect a dynamic interplay between tumor cells, platelets, and the tumor microenvironment: tumors alter platelet expression profiles while TEPs provide comprehensive molecular information about tumor genetics. This bidirectional relationship positions TEPs as highly promising biomarkers for early detection and non-invasive monitoring. Since early-stage breast cancer patients often achieve complete remission through surgery and standardized therapy, developing promising sensitivity and specific early diagnostic markers is crucial. Recently, liquid biopsy has gained significant momentum in breast cancer research, with TEPs emerging as particularly promising tools for cancer surveillance, treatment guidance, and diagnosis. This review examines TEP reprogramming mechanisms, current research advances, and the latest developments in TEP-based breast cancer applications (Graphical abstract).</div></div>","PeriodicalId":10205,"journal":{"name":"Clinica Chimica Acta","volume":"577 ","pages":"Article 120467"},"PeriodicalIF":3.2000,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Chimica Acta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009898125003468","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Tumor-educated platelets (TEPs) represent a novel approach in liquid biopsy, offering new perspectives for diagnosing, treating, and monitoring breast cancer. Unlike traditional histopathological biopsies—the current diagnostic gold standard—TEP-based detection is minimally invasive, requiring only peripheral blood samples and overcoming limitations of repeated invasive procedures. TEPs reflect a dynamic interplay between tumor cells, platelets, and the tumor microenvironment: tumors alter platelet expression profiles while TEPs provide comprehensive molecular information about tumor genetics. This bidirectional relationship positions TEPs as highly promising biomarkers for early detection and non-invasive monitoring. Since early-stage breast cancer patients often achieve complete remission through surgery and standardized therapy, developing promising sensitivity and specific early diagnostic markers is crucial. Recently, liquid biopsy has gained significant momentum in breast cancer research, with TEPs emerging as particularly promising tools for cancer surveillance, treatment guidance, and diagnosis. This review examines TEP reprogramming mechanisms, current research advances, and the latest developments in TEP-based breast cancer applications (Graphical abstract).

Abstract Image

查看原文本刊更多论文

肿瘤诱导血小板：乳腺癌诊断的新领域

肿瘤诱导血小板（TEPs）代表了液体活检的一种新方法，为乳腺癌的诊断、治疗和监测提供了新的视角。与传统的组织病理学活检（目前诊断的金标准）不同，基于tep的检测是微创的，只需要外周血样本，克服了重复侵入性手术的局限性。TEPs反映了肿瘤细胞、血小板和肿瘤微环境之间的动态相互作用：肿瘤改变血小板表达谱，而TEPs提供了有关肿瘤遗传学的全面分子信息。这种双向关系使tep成为早期检测和非侵入性监测的极有前途的生物标志物。由于早期乳腺癌患者通常通过手术和标准化治疗获得完全缓解，因此开发有希望的敏感性和特异性早期诊断标志物至关重要。最近，液体活检在乳腺癌研究中获得了显著的发展势头，tep作为癌症监测、治疗指导和诊断的特别有前途的工具出现。本文综述了TEP重编程机制、目前的研究进展以及基于TEP的乳腺癌应用的最新进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.